<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924638</url>
  </required_header>
  <id_info>
    <org_study_id>CRYSTAL-AF</org_study_id>
    <nct_id>NCT00924638</nct_id>
  </id_info>
  <brief_title>Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke</brief_title>
  <acronym>CRYSTAL-AF</acronym>
  <official_title>CRYptogenic STroke And underLying AF Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 2006 American Heart Association / American Stroke Association Council on Stroke
      Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic
      recommended that patients with cryptogenic stroke take antithrombotic drugs (i.e. aspirin) in
      order to prevent a second stroke. When a stroke patient is found to have atrial fibrillation
      (AF), the guidelines recommend oral anticoagulation due to its superior efficacy over aspirin
      for stroke prevention. Physicians can best optimize the use of medicines only if they can
      precisely and correctly diagnose a patient's AF. The purpose of this study is to evaluate the
      time to first AF by 6 months' continuous rhythm monitoring versus control treatment in
      subjects with a recent cryptogenic stroke or Transient Ischemic Attack (TIA) without history
      of AF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AF Detection Rate Within 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of subjects with AF detected within 6 months of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AF Detection Rate Within 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects with AF detected within 12 months of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Recurrent Stroke or TIA (Transient Ischemic Attack)</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects with recurrent stroke or TIA within 12 months of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Oral Anticoagulation (OAC) Drugs</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects who were using OAC drugs at the 12 months follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Antiarrhythmic Drugs</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects who were using antiarrhythmic drugs at the 12 months follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Outcome as Evaluated by EQ-5D Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>EQ-5D VAS (visual analog scale) quality of life score, which is a continuous measure of quality of life ranging from 0 (worst) to 100 (perfect health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Burden and Care Pathway</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of cardiovascular (CV) or stroke/TIA related hospitalizations within 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Patient Assistant Use on AF Diagnosis</measure>
    <time_frame>Follow-up closure</time_frame>
    <description>AF detection lag (days from AF occurrence to AF diagnosis) characterized by patient assistant (PA) use frequency</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">447</enrollment>
  <condition>Cryptogenic Symptomatic Transient Ischemic Attack</condition>
  <condition>Cryptogenic Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Continuous Monitoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reveal® XT Insertable Cardiac Monitor</intervention_name>
    <description>The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
    <arm_group_label>Continuous Monitoring</arm_group_label>
    <other_name>Reveal® XT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recent cryptogenic symptomatic transient ischemic attack (TIA) or cryptogenic ischemic
             stroke.

        Exclusion Criteria:

          1. Known etiology of TIA or stroke.

          2. Untreated hyperthyroidism.

          3. Myocardial infarction less than 1 month prior to stroke or TIA.

          4. Coronary bypass grafting less than 1 month prior to stroke or TIA.

          5. Valvular disease requiring immediate surgical intervention.

          6. History of AF or atrial flutter.

          7. Patent Foramen Ovale (PFO) and PFO is or was an indication to start oral
             anticoagulation (OAC).

          8. Permanent indication for OAC at enrollment.

          9. Permanent contra-indication for OAC.

         10. Included in another clinical trial.

         11. Life expectancy less than 1 year.

         12. Pregnant.

         13. Indicated for Implantable Pulse Generator (IPG), Implantable
             Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT) or an
             implantable hemodynamic monitoring system.

         14. Not fit, unable or unwilling to follow the required procedures of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Brachmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Coburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tommaso Sanna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Christoph Diener, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Neurologie, Essen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Morillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster Clinic, Hamilton, Ontario, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Bernstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davee Department of Neurology, Chicago, IL USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincenzo Di Lazzaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Rome, Rome Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rod Passman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Memorial Hospital, Chicago, IL USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilyn Rymer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Lukes Hospital of Kansas City, Kansas City, MI USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology / Swedish Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart / Ruan Neurology</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Cardiology</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates Research, LLC</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute / St. Lukes Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Bucks Specialists / Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System Cardiology/Cardiovascular Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Donauregion Tulln</name>
      <address>
        <city>Tulln</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brussels Heart Center (St. Lean - St. Pierre)</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires UCL Mont-Godinne</name>
      <address>
        <city>Mont Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences / Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS / Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology clinic, Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André -CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Parly II - Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH</name>
      <address>
        <city>Coburg</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMG, Goettingen</name>
      <address>
        <city>Goettingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Altona</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Barmbek</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe GmbH</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Rastatt</name>
      <address>
        <city>Rastatt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Dunant General Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Misericordia di Grosseto</name>
      <address>
        <city>Grosseto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Imperia</name>
      <address>
        <city>Imperia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bolognini</name>
      <address>
        <city>Seriate</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NUSCH, a.s. Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUSCH Kosice</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T; American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006 Feb;37(2):577-617.</citation>
    <PMID>16432246</PMID>
  </reference>
  <reference>
    <citation>Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am Heart J. 2010 Jul;160(1):36-41.e1. doi: 10.1016/j.ahj.2010.03.032.</citation>
    <PMID>20598970</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <results_first_submitted>June 26, 2014</results_first_submitted>
  <results_first_submitted_qc>June 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2014</results_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>cryptogenic stroke</keyword>
  <keyword>continuous monitoring</keyword>
  <keyword>implantable loop recorder</keyword>
  <keyword>insertable cardiac monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 447 subjects were enrolled in 55 study centers from 14 countries in North America and Europe, during the recruitment period of June 2009 to April 2012.</recruitment_details>
      <pre_assignment_details>A total of 6 enrolled subjects were exited from the study prior to randomization due to: Eligibility criteria not met (n=4), and Subject withdrew consent (n=2).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Continuous Monitoring</title>
          <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221">Randomized to Continuous Monitoring Arm</participants>
                <participants group_id="P2" count="220">Randomized to Control Arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209">Completed 6 months of follow-up</participants>
                <participants group_id="P2" count="207">Completed 6 months of follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
      <group_list>
        <group group_id="B1">
          <title>Continuous Monitoring</title>
          <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
            <count group_id="B2" value="220"/>
            <count group_id="B3" value="441"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="11.4"/>
                    <measurement group_id="B2" value="61.4" spread="11.3"/>
                    <measurement group_id="B3" value="61.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AF Detection Rate Within 6 Months</title>
        <description>Percentage of subjects with AF detected within 6 months of follow-up</description>
        <time_frame>6 months</time_frame>
        <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Monitoring</title>
            <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>AF Detection Rate Within 6 Months</title>
          <description>Percentage of subjects with AF detected within 6 months of follow-up</description>
          <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>21.7</ci_upper_limit>
            <estimate_desc>A hazard ratio of &gt; 1 indicates that Continuous Monitoring is superior to Control in detecting AF.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AF Detection Rate Within 12 Months</title>
        <description>Percentage of subjects with AF detected within 12 months of follow-up</description>
        <time_frame>12 months</time_frame>
        <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Monitoring</title>
            <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>AF Detection Rate Within 12 Months</title>
          <description>Percentage of subjects with AF detected within 12 months of follow-up</description>
          <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>20.8</ci_upper_limit>
            <estimate_desc>A hazard ratio of &gt; 1 indicates that Continuous Monitoring is superior to Control in detecting AF.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Recurrent Stroke or TIA (Transient Ischemic Attack)</title>
        <description>Percentage of subjects with recurrent stroke or TIA within 12 months of follow-up</description>
        <time_frame>12 months</time_frame>
        <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Monitoring</title>
            <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Recurrent Stroke or TIA (Transient Ischemic Attack)</title>
          <description>Percentage of subjects with recurrent stroke or TIA within 12 months of follow-up</description>
          <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>A hazard ratio of &lt; 1 indicates that the incidence rate of recurrent stroke or TIA is lower in the Continuous Monitoring arm compared to the Control arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Oral Anticoagulation (OAC) Drugs</title>
        <description>Percentage of subjects who were using OAC drugs at the 12 months follow-up visit</description>
        <time_frame>12 months</time_frame>
        <population>Number of subjects who completed the 12-months follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Monitoring</title>
            <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Oral Anticoagulation (OAC) Drugs</title>
          <description>Percentage of subjects who were using OAC drugs at the 12 months follow-up visit</description>
          <population>Number of subjects who completed the 12-months follow-up visit</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>14.8</ci_upper_limit>
            <estimate_desc>A difference of greater than 0 means that a higher percentage of subjects in the Continuous Monitoring arm were using the OAC drugs at the 12 months visit compared to the Control arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Antiarrhythmic Drugs</title>
        <description>Percentage of subjects who were using antiarrhythmic drugs at the 12 months follow-up visit</description>
        <time_frame>12 months</time_frame>
        <population>Number of subjects who completed the 12 months follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Monitoring</title>
            <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Antiarrhythmic Drugs</title>
          <description>Percentage of subjects who were using antiarrhythmic drugs at the 12 months follow-up visit</description>
          <population>Number of subjects who completed the 12 months follow-up visit</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
            <estimate_desc>A difference of greater than 0 means that a higher percentage of subjects in the Continuous Monitoring arm were using the anti-arrhythmic drugs at the 12 months visit compared to the Control arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Outcome as Evaluated by EQ-5D Questionnaire</title>
        <description>EQ-5D VAS (visual analog scale) quality of life score, which is a continuous measure of quality of life ranging from 0 (worst) to 100 (perfect health).</description>
        <time_frame>12 months</time_frame>
        <population>Number of subjects who reported EQ-5D VAS score at the 12 months visit</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Monitoring</title>
            <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Health Outcome as Evaluated by EQ-5D Questionnaire</title>
          <description>EQ-5D VAS (visual analog scale) quality of life score, which is a continuous measure of quality of life ranging from 0 (worst) to 100 (perfect health).</description>
          <population>Number of subjects who reported EQ-5D VAS score at the 12 months visit</population>
          <units>units on a scale of 0 to 100</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" spread="15.6"/>
                    <measurement group_id="O2" value="76.3" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Disease Burden and Care Pathway</title>
        <description>Incidence of cardiovascular (CV) or stroke/TIA related hospitalizations within 12 months</description>
        <time_frame>12 months</time_frame>
        <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Monitoring</title>
            <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Disease Burden and Care Pathway</title>
          <description>Incidence of cardiovascular (CV) or stroke/TIA related hospitalizations within 12 months</description>
          <population>Intention-to-treat (ITT) population (all randomized subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
            <estimate_desc>A hazard ratio of &lt; 1 indicates that the incidence rate of cardiovascular or stroke/TIA related hospitalization is lower in the Continuous Monitoring arm compared to the Control arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Patient Assistant Use on AF Diagnosis</title>
        <description>AF detection lag (days from AF occurrence to AF diagnosis) characterized by patient assistant (PA) use frequency</description>
        <time_frame>Follow-up closure</time_frame>
        <population>Number of subjects in the Continuous Monitoring arm who had AF detected by the Insertable Cardiac Monitor (ICM) during the course of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Monitoring</title>
            <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Patient Assistant Use on AF Diagnosis</title>
          <description>AF detection lag (days from AF occurrence to AF diagnosis) characterized by patient assistant (PA) use frequency</description>
          <population>Number of subjects in the Continuous Monitoring arm who had AF detected by the Insertable Cardiac Monitor (ICM) during the course of the study</population>
          <units>days from AF occurrence to AF diagnosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PA used everyday</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA used most of the time (5-6 days/week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA used sometimes (3-4 days/week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.8" spread="235.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA used rarely (1-2 days/week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA never used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0">Only one observation was available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA use frequency not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0">Only one observation was available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the study (from enrollment to exit). Average subject follow-up duration was 19.7 +/- 9.7 months (range: 0 - 42.7 months).</time_frame>
      <desc>Subjects were assessed for adverse events through scheduled follow-up visits at 6 month intervals, as well as through unscheduled visits as adverse events occur.</desc>
      <group_list>
        <group group_id="E1">
          <title>Continuous Monitoring</title>
          <description>Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
Reveal® XT Insertable Cardiac Monitor: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Follow-up at the same frequency, but with no Insertable Cardiac Monitor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pocket erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chondrolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Soft tissue disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cerebrovascular spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Somatisation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="60" subjects_affected="41" subjects_at_risk="221"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medtronic CRDM clinical trial manager</name_or_title>
      <organization>Medtronic, Inc.</organization>
      <phone>763-505-6000</phone>
      <email>medtronicCRMtrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

